Clinical trials: Multiple Myeloma, Neoplasms
Cancer
A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers
The purpose of this study is to determine whether the MEK inhibitor and the AKT inhibitor can be given in combination and if the combination is effective treatment for patients with solid tumors, including breast cancer and…
- Trial name
- NCT01476137
- Testing
- GSK1120212, GSK2110183
- Where
- 2 sites in United States
- Volunteers
- 335 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to determine if there is an improvement in progression-free survival (length of time during and after treatment in which a patient is living with a disease that does not get worse) when siltuximab is…
- Trial name
- NCT01266811
- Testing
- Siltuximab, Velcade and dexamethasone
- Where
- 48 sites in United States, Australia and 12 more
- Sponsor
- Centocor, Inc.
Multiple Myeloma, Non-Hodgkins Lymphoma
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
The purpose of this study is to determine whether it is safe and effective to collect peripheral blood hematopoietic stem cells 16 hours rather than the usual 11 hours after administration of plerixafor.
- Trial name
- NCT01042717
- Testing
- Plerixafor
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Shi, Patricia, M.D.
Cancer, Multiple Myeloma
Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study
The goal of this study is to evaluate the safety of melphalan and autologous PBSCT (peripheral blood stem cell transplantation - stem cells that come from your own body) in combination with bortezomib, a new FDA approved drug…
- Trial name
- NCT00793650
- Testing
- Bortezomib, Melphalan, Autologous PBSC Transplant
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Emory University
Multiple Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
Background: Carfilzomib is an experimental anti-cancer drug that has not yet been approved for treating multiple myeloma. Lenalidomide is a drug that may stop tumor growth and help the immune system kill cancer cells.
- Trial name
- NCT01402284
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
The purpose of this study is to evaluate the efficacy and safety of ixazomib, oral dexamethasone and in patients with relapsed multiple myeloma who have received lenalidomide.
- Trial name
- NCT04989140
- Testing
- Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Multiple Myeloma and Plasma Cell Neoplasm
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Thalidomide may slow the growth of cancer cells. Oblimersen may increase the effectiveness of thalidomide and dexamethasone by making cancer cells more sensitive to the drugs.
- Trial name
- NCT00049374
- Testing
- oblimersen sodium, dexamethasone, thalidomide
- Where
- 2 sites in United States
- Sponsor
- University of Maryland, Baltimore
Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma
B-Cell Hematologic Malignancy Vaccination Registry
The goal of this study is to develop a vaccination registry system for Aurora Health Care patients newly diagnosed with MM and other B-Cell Hematologic Malignancies in order to prospectively characterize vaccination history and…
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Waldenstrom Macroglobulinemia, Lymphocytosis
- Trial name
- HMvax-Regist (NCT02298816)
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Multiple Myeloma
To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in Patients With Multiple Myeloma
The purpose of this study is to determine whether surgical treatment, balloon kyphoplasty is more effective compared to conservative treatment alone (sham procedure) when assessing clinical, translational, radiological \& patient…
- Trial name
- MELODY (NCT02732925)
- Testing
- Arm 2 Balloon Kyphoplasty, Conservative Management
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- Royal National Orthopaedic Hospital NHS Trust
Multiple Myeloma
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
The goal of this clinical trial is to compare a maintenance therapy consisting of iberdomide and isatuximab with an iberdomide-only regimen.
- Trial name
- NCT06216158
- Testing
- Iberdomide, Isatuximab, Dexamethasone
- Where
- 69 sites in Austria, Germany
- Volunteers
- 411 people
- Sponsor
- University of Heidelberg Medical Center
Lymphoma Neoplasms, Myeloma Multiple
Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.
This is a prospective, multicenter, observational cohort study involving patients with hematologic malignancies who are receiving bispecific antibody therapy.
- Conditions
- Lymphoma Neoplasms, Myeloma Multiple, Severe Infection, CMV Reactivation
- Trial name
- NCT07609576
- Where
- 2 sites in Spain
- Volunteers
- 350 people
- Sponsor
- Infanta Leonor University Hospital
RSV Infection
RSV Vaccination in Immunocompromised Patients.
Respiratory syncytial Virus (RSV) causes respiratory infections worldwide and typically presents with a seasonal pattern peaking in autumn/winter in temperate climate zones.
- Trial name
- NCT06597916
- Testing
- Arexvy powder and suspension for injection
- Where
- Austria
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Multiple Myeloma
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Study of the efficacy and safety of bortezomib administered in combination with vorinostat in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT00773747
- Testing
- Vorinostat, bortezomib
- Volunteers
- 637 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
- Conditions
- Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03844048
- Testing
- Venetoclax
- Where
- 56 sites in United States, Australia and 21 more
- Volunteers
- 165 people
- Sponsor
- AbbVie
Multiple Myeloma
Diagnostic Imaging of Myeloma Bone Lesions
The purpose of this study is to compare the current standard whole-body x-ray with the advanced imaging techniques FDG-PET-CT, NaF-PET-CT and whole-body MRI in the detection of myeloma bone lesions.
- Trial name
- RAMP (NCT03147326)
- Testing
- FDG-PET-CT, NaF-PET-CT, Whole-body MRI
- Where
- Denmark
- Volunteers
- 14 people
- Sponsor
- Herlev Hospital
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
This is a non-randomised, open-label phase I study of an investigational medicinal product (IMP) consisting of a HLA-A*02:01 restricted HA-1H T cell receptor transduced T cell (MDG1021) immunotherapy for relapsed or persistent…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
- Trial name
- NCT04464889
- Testing
- MDG1021 dose 1, MDG1021 dose 2, MDG1021 dose 3
- Where
- Netherlands
- Sponsor
- Medigene AG
Multiple Myeloma
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
This phase I trial studies the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor [CAR] T-cell therapy) in patients with multiple…
- Trial name
- NCT06048250
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Myeloma
Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning
Donor mobilization : Donor will be mobilized with G-CSF (Granocyte) sub-cutaneous 10 µg/kg/day during 5 to 6 days. Hematopoïetic Stem Cell Harvest: By 1, 2, or 3 aphaeresis, a number of 4 x 106 cellules CD34+ /kg is required.
- Trial name
- IFM 2005-03 (NCT00466674)
- Testing
- reduced intensity conditioning
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Hospices Civils de Lyon
Myeloma
Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients
Clinically demonstrated efficacy of Melphalan and Prednisone in MM subjects as well as the confirmed inhibitory effect of dasatinib on several tyrosine kinase receptors and pathways implicated in the pathophysiology of MM.
- Trial name
- D-MP (NCT01116128)
- Testing
- dasatinib, melphalan, prednisone
- Where
- Italy
- Volunteers
- 8 people
- Sponsor
- Fondazione EMN Italy Onlus
Multiple Myeloma
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
This study is designed to define dose-limiting toxicity and determine preliminary evidence of efficacy of carfilzomib (CFZ) in combination with bendamustine and dexamethasone for patients with newly diagnosed multiple myeloma…
- Trial name
- NCT02002598
- Testing
- Bendamustine, Carfilzomib, Dexamethasone
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Suzanne Lentzsch, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.